Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > HGSI > Summary

Human Genome Sciences Inc.
(HGSI)

27.06USD   Up1.30 (5.05%)   
At 2:30AM IST
 Human Genome Sciences Inc. (NGM:HGSI) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 27.06USD
Trade Time:2:30AM IST
Change:Up1.30 (5.05%)
Prev Close:25.76
Open:26.12
Bid:26.50 x 500
Ask:N/A
1y Target Est:34.07
Day's Range:26.06 - 27.19
52wk Range:0.45 - 32.07
Volume:4,295,657
Avg Vol (3m):4,153,480
Market Cap:4.47B
P/E (ttm):N/A
EPS (ttm):-0.16
Div & Yield:N/A (N/A%)
Add HGSI to Portfolio   Download Data

HEADLINES

 
•UK court overturns GSK patent for lupus drug - FT.com  - Wed 4:40AM
•UK court rules HGS gene patent invalid -lawyers - Reuters  - Tue 10:09PM
•Biotech ETFs Immune To Broad Selling - Investor's Business Daily  - Tue 4:04AM
•[$$] Biotech ETFs Are Looking Healthy - RealMoney by TheStreet.com  - Tue 3:20AM
•Friday Options Recap: Defensive Trading - Seeking Alpha  - Sat, Feb 6
•Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO Investor Conference - Business Wire  - Fri, Feb 5
•Glaxo Brings Home the Bacon - Motley Fool  - Fri, Feb 5
•The Answer You've Been Waiting For - Motley Fool  - Wed, Feb 3
•3 Best Hedge Fund Healthcare Ideas - Seeking Alpha  - Wed, Feb 3
•Human Genome Sciences Names Scott Habig Vice President, Sales - Business Wire  - Mon, Feb 1
•Research And Development Expenditures In Diagnostic And Lab Equipment Sector Raises Capital Requirements: Will Acquisitions By Larger Health Care Companies Be The Result? - Wall Street Transcript  - Thu, Jan 28
•Coverage initiated on Human Genome by RBC Capital Mkts - Briefing.com  - Wed, Jan 27
» More Headlines for HGSI...

ANALYST

 
EPS Est (next year) (Dec-09) :0.05
EPS Est (in 2 years) (Dec-10) :-0.72
Avg Rec (current)*:1.7
PEG Ratio:120.60
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company’s clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer.

» Full Company Profile